These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22846813)

  • 1. C3 glomerulopathy: what's in a name?
    D'Agati VD; Bomback AS
    Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far.
    Larsen CP; Walker PD
    Kidney Int; 2013 Feb; 83(2):331-2. PubMed ID: 23364589
    [No Abstract]   [Full Text] [Related]  

  • 3. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The authors reply:
    Servais A; Noel LH; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2013 Feb; 83(2):332-3. PubMed ID: 23364592
    [No Abstract]   [Full Text] [Related]  

  • 5. Dense deposit disease and C3 glomerulopathy.
    Barbour TD; Pickering MC; Terence Cook H
    Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
    Hawfield A; Iskandar SS; Smith RJ
    Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
    J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
    Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
    Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a working definition of C3 glomerulopathy by immunofluorescence.
    Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
    Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.
    Besbas N; Gulhan B; Gucer S; Korkmaz E; Ozaltin F
    J Nephrol; 2014 Aug; 27(4):457-60. PubMed ID: 24536001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in the complement system in membranoproliferative glomerulonephritis].
    Yurova VA; Bobrova LA; Kozlovskaya NL; Korotchaeva YV; Serova AG; Kozlov LV; Andina SS; Demyanova KA; Kuchieva AM; Roshchupkina SV
    Ter Arkh; 2017; 89(6):69-77. PubMed ID: 28745692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C3 glomerulopathy and current dilemmas.
    Ito N; Ohashi R; Nagata M
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
    Licht C; Fremeaux-Bacchi V
    Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
    Xiao X; Pickering MC; Smith RJ
    Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
    Sethi S; Nester CM; Smith RJ
    Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.